The Clarifi autism
saliva test

Clarifi ASD is designed to provide a probability of an autism diagnosis based on epigenetic biomarkers in the saliva for children 18 months through 6 years of age.

Simple
Simple

Non-invasive and easily administered at-home saliva test

Rapid
Timely

Accelerates the diagnostic process with results in 3 to 6 weeks

Validated
Objective

Based on peer-reviewed research 

Objective
Molecular

Measures epigenetic molecules in saliva

collage wide
Collage Square

Is your child eligible for Clarifi ASD?

Clarifi ASD is appropriate for children who meet the following eligibility requirements.

Blue-CheckSuspicion of autism

For children with a clinical suspicion of autism, such as a positive screen on M-CHAT-R

Blue-CheckAppropriate age range

Must be 18 months through 6 years of age

Blue-CheckMeets geographic requirements

Clarifi ASD will be available in the U.S.

The road to Clarifi ASD

Read about our team’s journey translating a medical discovery into an innovative clinical product.

CHALLENGE

Rising autism prevalence and
longer wait times for diagnosis

According to the CDC, 1 in 44 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. A biological, diagnostic tool can further inform clinical judgment and substantially improve early identification.

CHALLENGE

Rising autism prevalence and longer wait times for diagnosis

According to the CDC, 1 in 54 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. A biological, diagnostic tool can further inform clinical judgment and substantially improve early identification.

Rising autism prevalence and longer wait times for diagnosis

“There has clearly been an increase in prevalence of autism spectrum disorder in our society. Our goal is to facilitate diagnosis in younger children and maximize the potential for interventions to improve abilities, outcomes and quality of life.”

Kayla circle
Kayla Wagner

President – ASD Diagnostic Products, Quadrant Biosciences
Cutting-edge breakthroughs in epigenetic research

DISCOVERY

Cutting-edge breakthroughs in epigenetic research

Clarifi ASD is not a genetic test. It is the product of scientific advancements in the area of epigenetics; the factors that influence how genes are turned on and off. Our peer-reviewed research discovered that certain RNA molecules that regulate genetic activity and reflect interactions between a patient and their environment, were different in children with autism.

DEVELOPMENT

Translating the science into practical solutions

Quadrant Biosciences’ unique bioinformatics platform and CLIA-certified Laboratories facilitate the development and validation of Laboratory Developed Tests (LDTs) to turn novel discoveries into clinically available solutions.

Translating the science into practical solutions

“A test which can separate children who have screened M-CHAT positive into high likelihood of autism or low likelihood of autism could help streamline waitlists and permit earlier diagnosis and enrollment in autism treatment.”

Daniel Coury
Dr. Daniel Coury MD

Professor of Pediatrics and Psychiatry at College of Medicine at The Ohio State University and the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital
Diagnosis is only the first step

RESOURCES

Diagnosis is only the first step

Quadrant Biosciences is proud to support Autism Speaks in providing resources and solutions to individuals and families touched by autism. In your patient account, you will find links to resources such as toolkits, local service provider directories and other helpful information.
Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the lifespan, for the needs of individuals and their families.

smile-background-shadow-012-1
We’ve partnered with top research and support organizations

“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”

Rich Uhlig
Richard Uhlig

Founder and CEO, Quadrant Biosciences

Subscribe to Clarifi ASD

Get important details in your inbox